Abbott (ticker: ABT, exchange: New York Stock Exchange (.N))
News Release -
21-Jul-2009
Abbott Launches New Instrument to Complete Family of ARCHITECT Immunochemistry Analyzers Abbott's new c4000 system delivers sophisticated science in a compact
footprint
CHICAGO, July 21 /PRNewswire-FirstCall/ -- Today at the American
Association for Clinical Chemistry's Clinical Lab Expo in Chicago, Abbott
(NYSE: ABT) announced the launch of a new diagnostic instrument -- the
ARCHITECT c4000 clinical chemistry analyzer which performs diagnostic tests
that monitor general health including a patient's levels of sodium, potassium,
chloride and organ function.
The new ARCHITECT c4000 seamlessly integrates with Abbott's i1000SR
immunoassay analyzer to form the ARCHITECT ci4100(TM), an automated analyzer
that completes both immunoassay and chemistry tests on one platform. With
these two products, Abbott now offers chemistry, immunoassay, and integrated
diagnostic testing solutions to improve the performance and efficiency of
laboratories of all sizes.
Abbott is the only company offering high, medium and low-volume integrated
diagnostic testing solutions that leverage the same software, reagents and
sample carriers. Standardizing to a single family of instruments like Abbott's
ARCHITECT products gives labs the ability to optimize processes, minimize
errors, and reduce result variability, which is becoming increasingly
important as clinicians rely more and more on laboratory diagnostics to guide
their treatment decisions.
Abbott's family of ARCHITECT instruments generates accurate and equivalent
results across instruments and labs, even at multiple sites, because these
instruments share detection technologies, reagents, and software. This
standardization is critical as hospitals and the Obama administration continue
to emphasize the importance of capturing patient histories in electronic
medical records. In a recent study of U.S. hospitals, 73 percent of health
care decision makers and executives identified electronic medical records
(EMR) as one of their top priorities for 2009.
"Standardized results across laboratory instruments is increasingly
important as the reputation of the laboratory and its influence on quality
healthcare depends on providing consistent, fast and accurate results to
enable the medical staff on site and in other locations to make critical
treatment decisions," said Michael Warmuth, senior vice president,
diagnostics, Abbott. "We're pleased that Abbott can meet these and other
critical needs of laboratories through our complete family of ARCHITECT
products."
In addition to standardization across instruments, Abbott's ARCHITECT
c4000 and ci4100 are designed to deliver improved productivity to lower volume
laboratories. The c4000 analyzer can generate up to 800 test results per hour
while the ci4100 integrated system can generate up to 900 test results per
hour. With an extensive menu of diagnostic tests and a large sample and
reagent load-up capacity, the ARCHITECT c4000 and ci4100 can consolidate a
laboratory's workload to increase efficiency and save costs. ARCHITECT
instruments are simple to operate with advanced sample management capabilities
from the innovative three-dimensional Robotic Sample Handler. With this
feature, once manual steps are now automated, which saves laboratories time
and money and better meets their increased testing demands.
In addition, Abbott's integrated instruments are the only products on the
market that feature no clinically significant sample-to-sample carryover, less
than 0.1 parts per million, without resorting to unnecessary sample handling,
plastic disposables like pipette tips or extended processing times due to the
risk of contamination.
"We evaluated the ARCHITECT c4000 with one of our partner laboratories and
found that the ARCHITECT c4000 provides laboratory efficiencies with
commonality and equivalent results across the family," said Rob Kerekes,
chemistry charge technologist at Huron-Perth Healthcare Alliance in Stratford,
Ontario, Canada. "The c4000 is ideal for laboratories requiring a reliable
analyzer that takes up less space."
About the ARCHITECT Instrument Family
The ARCHITECT family of analyzers includes the i1000SR and i2000SR for
immunoassay testing, the c4000, c8000, and c16000 for clinical chemistry
testing, and the ci4100, ci8200, and ci16200 integrated immunoassay/chemistry
systems. Abbott's unique technologies include the Robotic Sample Handler to
prioritize emergency tests; sample clot and bubble detection to verify
sampling integrity; and FlexRate and CHEMIFLEX assay technologies. ARCHITECT
systems use identical easy-to-use software and common reagents across all
members of the family, ensuring fast and accurate results while requiring a
very small sample volume, resulting in improved performance. These features
not only save laboratories' time by reducing the time needed for instrument
training, testing and troubleshooting, but also reduce inventory costs and
reduce the potential for sample contamination -- leading to better results for
laboratories, physicians and, ultimately, patients.
About Abbott Diagnostics
Abbott Diagnostics is a global leader in in vitro diagnostics and offers a
broad range of innovative instrument systems and tests for hospitals,
reference labs, blood banks, physician offices and clinics. With more than
69,000 institutional customers in more than 100 countries, Abbott's diagnostic
products offer customers automation, convenience, cost effectiveness and
flexibility. Abbott has helped transform the practice of medical diagnostics
from an art to a science through the company's commitment to improving patient
care and lowering overall costs. The history of Abbott Diagnostics is filled
with examples of first-of-a-kind products and significant technological
advancements, including the development of the very first diagnostic test to
detect HIV.
About Abbott
Abbott is a global, broad-based health care company devoted to the
discovery, development, manufacture and marketing of pharmaceuticals and
medical products, including nutritionals, devices and diagnostics. The company
employs more than 72,000 people and markets its products in more than 130
countries.
Abbott's news releases and other information are available on the
company's Web site at www.abbott.com.
ARCHITECT, i1000SR, i2000SR, c4000, c8000, c16000, ci4100, ci8200,
ci16200, CHEMIFLEX and FlexRate are trademarks of Abbott Laboratories.
CONTACT: Media, Ann Fahey-Widman, +1-847-938-6388, or Financial, Tina
Ventura, +1-847-935-9390, both of Abbott
Web Site: http://www.abbott.com
|